Omeros (NASDAQ:OMER) CAO David Borges Sells 906 Shares of Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 906 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $19.10, for a total value of $17,304.60. Following the transaction, the chief accounting officer directly owned 5,906 shares of the company’s stock, valued at $112,804.60. This represents a 13.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Down 0.2%

Shares of NASDAQ:OMER opened at $19.28 on Wednesday. The company has a market cap of $1.40 billion, a price-to-earnings ratio of 15.06 and a beta of 2.54. The business has a 50 day moving average price of $12.12 and a 200 day moving average price of $11.87. Omeros Corporation has a twelve month low of $3.94 and a twelve month high of $19.65.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. Analysts anticipate that Omeros Corporation will post -0.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright reiterated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Omeros in the second quarter valued at about $57,484,000. Vanguard Group Inc. boosted its holdings in Omeros by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after buying an additional 666,357 shares during the last quarter. UBS Group AG boosted its holdings in Omeros by 213.5% during the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after buying an additional 1,513,893 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Omeros by 6.3% during the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock worth $28,026,000 after buying an additional 95,979 shares during the period. Finally, State Street Corp grew its position in shares of Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after buying an additional 333,798 shares during the period. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.